FCGRT and myasthenia gravis: Preclinical studies showed safety and efficacy of an anti-FcRn monoclonal antibody, 1G3, in a passive and active model of EAMG: in rats in which MG was induced by passive transfer of anti-AChR antibodies, 1G3 treatment resulted in dose-dependent improvement of symptoms and reduction of pathogenic antibody levels in serum; in rats immunized with the AChR, the treatment significantly reduced the severity of the disease symptoms and the levels of both total IgG and anti-AChR antibodies (89).